Imaging clinical research organization ImageIQ will participate in a vascular research study being performed on the last flight of the space shuttle Atlantis.
The Cleveland-based company will acquire and analyze images used in a study of space flight-induced vascular changes in the lower leg, according to a statement from ImageIQ. Specifically, the study will examine a therapy that’s designed to prevent space flight-induced bone loss in mice.
The study is being funded by NASA and builds on research performed at Cleveland Clinic, and led by Ronald Midura of the Clinic’s biomedical engineering department. ImageIQ was spun off from Cleveland Clinic and was funded through a grant to the Clinic from Ohio’s Third Frontier technology support program.
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
The study is a collaboration between NASA, Colorado-based research group BioServe Space Technologies and drug manufacturer Amgen, according to the statement.
ImageIQ’s business model is to help drug and device firms, plus research organizations, analyze images they’ve collected in preclinical and clinical trials through technology such as MRIs or CT scans. ImageIQ doesn’t do imaging itself. Rather, it gathers images from clients, then runs the images through various proprietary software programs that produce clinical data obtained from the image.
Atlantis’s last flight is scheduled to launch around midday on Friday, July 8, in Cape Canaveral, Florida, but weather concerns could push the launch back.
